Overview

Jin Ooi is an intellectual property litigator in the London office of Kirkland & Ellis International LLP. He is experienced in patent litigation and counselling (including on complex damages inquiries) mainly in the pharmaceutical and life sciences field (second medical use, small molecules, DNA sequencing, vaccines, transgenic animal platforms for antibody discovery), and in the consumer products sector (shaving razors, next generation vaping products, coffee pods and capsules). He is also experienced in litigating and arbitrating trade secrets disputes in the medical devices (bone cements), tech (LNG carriers) and aviation sector (airplane components, airport businesses), in addition to handling antitrust claims (cathode ray tubes, lithium ion batteries, forklift gas). His clients have included Pfizer, Novartis, Regeneron, Samsung, Biomet and Procter & Gamble. Jin’s cases are often multi-jurisdictional requiring significant cross-border coordination across multiple forums.

Prior to joining Kirkland, Jin worked at Allen & Overy LLP in London for 4 years and before that Corrs Chambers Westgarth in Sydney for 3½ years. In recognition of his work in Australia, Jin was among a select few young lawyers awarded the 2014 Lawyers Weekly 30 Under 30 Awards, and a finalist in two categories in the 2015 Awards. His dual qualifications in law (1st class degree) and pharmacology give him a special insight into, and understanding of, his clients’ legal needs and commercial and regulatory imperatives.

More

Thought Leadership

Publications

“Patent Litigation 2019: Trends and Developments”, Chambers and Partners Practice Guides, 2019

“UK Patent Law: Hot Topics of 2018 and What’s Ahead”, Law360, 2019

“Actavis v Eli Lilly: outcomes”, IPPro, 2018

"Book review: Intellectual Property in Australia", The IPKat, 2017

"Applying Cartier v. BSkyB to UK life sciences patents", Law360, 2016

"Caught in the middle: ISPs face blocking orders after Cartier case", Intellectual Property Magazine, 2016

"The utility of the Cartier case in the life sciences context", Intellectual Property Magazine, 2016

"The International Arbitration Review (Chapter: Australia)" (3rd, 4th and 5th eds), Law Business Research, 2012-2014

Seminars

Speaker, “Insufficiency and the many shades of plausibility”, Young EPLAW Congress, Brussels, 2018

Speaker, "Where are we now with plausibility?", Young EPLAW Congress, Brussels, 2017

Speaker, "What companies need to know about the Bolar exemption", C5 EU Pharmaceutical Regulatory Law conference, London, 2016

Speaker, "Implications of Brexit for IP and IT legal practice", LexisNexis webinar, London, 2016

Speaker, “Second medical use - the UK perspective”, Future of Innovation in Medicine: Incentives for New Medical Treatments and Global Health conference, Seattle, 2015

Moderator, “Drug development and approval process with its part in exclusivity”, Future of Innovation in Medicine: Incentives for New Medical Treatments and Global Health conference, Seattle, 2015

Memberships & Affiliations

The Law Society of England & Wales

The Law Society of New South Wales (Australia)

AIPPI: International Association for the Protection of Intellectual Property

IPSoc

  • Education Secretary

Credentials

Admissions & Qualifications

  • 2017, Entitled to exercise Higher Rights of Audience (Civil Advocacy)
  • 2016, Admitted to Practice as a Solicitor of England and Wales
  • 2012, Admitted to Practice as a Solicitor in the federal courts of Australia
  • 2011, Admitted to Practice as a Solicitor of New South Wales, Australia

Education

  • University of OxfordPostgraduate Diploma in Intellectual Property Law and Practice2016
  • College of Law, SydneyGraduate Diploma in Legal Practice2011
  • The University of SydneyLL.B.First Class Honours2010
  • The University of SydneyB.Sc., PharmacologyAdvanced2008